0000880771-16-000185.txt : 20160816
0000880771-16-000185.hdr.sgml : 20160816
20160816174107
ACCESSION NUMBER: 0000880771-16-000185
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160812
FILED AS OF DATE: 20160816
DATE AS OF CHANGE: 20160816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 161836979
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2016-08-12
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President & CEO
Common Stock
2016-08-12
4
M
0
3500
0
A
463782
D
Common Stock
2016-08-12
4
M
0
5000
0
A
468782
D
Common Stock
2016-08-12
4
M
0
50000
0
A
518782
D
Common Stock
2016-08-12
4
F
0
1827
10.41
D
516955
D
Common Stock
2016-08-12
4
F
0
26090
10.41
D
490865
D
Common Stock
2016-08-12
4
F
0
2610
10.41
D
488255
D
Restricted Stock Unit
2016-08-12
4
A
0
40000
0
A
Common Stock
40000
383500
D
Restricted Stock Unit
2016-08-12
4
M
0
3500
0
D
Common Stock
3500
380000
D
Restricted Stock Unit
2016-08-12
4
M
0
5000
0
D
Common Stock
5000
375000
D
Restricted Stock Unit
2016-08-12
4
M
0
50000
0
D
Common Stock
50000
325000
D
Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2016.
Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
Granted under the Issuer's 2015 Equity Incentive Plan.
Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
Granted under the Issuer's 2005 Equity Incentive Plan.
Vesting for such RSUs will occur 50% on February 20, 2015 and 50% on February 20, 2016, or on such later date thereafter as the Company's trading window opens if it is not open on either of such dates.
Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
Vesting to be in three equal annual installments at the close of business on the first business day following December 31 of each of calendar year 2015, 2016, and 2017, provided that the Participant's service with the Company has not terminated prior to the applicable vesting time.
Friedhelm Blobel, Ph.D.
2016-08-16